India's Wockhardt buys CP Pharma

- Last updated on GMT

Related tags: Europe, Pharmacology, India

India's Wockhardt has acquired CP Pharmaceuticals in a deal valued
at £10.9 million (€15.6m) that grows the Indian firm's UK market
presence.

Indian drugmaker Wockhardt has acquired UK-based CP Pharmaceuticals in a deal valued at £10.9 million (€15.6m) that grows the Indian firm's UK market presence, as well as creating a larger manufacturing base from which to expand its business into other European markets.

CP has four main business areas including a branded portfolio of drugs sold in the hospital setting, generic products, contract manufacturing and exports. The acquisition of the Wrexham, Wales-headquartered firm will bring Wockhardt's annual UK sales to around £50 million, noted the company.

CP Pharma has an exclusive manufacturing contract for one of Eli Lilly's pipeline products, currently in Phase III trials, according to a report in the Express Pharma Pulse.

Commenting on the deal, Wockhardt chairman Habil Khorakiwala said he had acquired a "leading player in the UK generic space, "​ adding: "Wockhardt has global strengths in manufacturing and research which we will leverage to drive CP's growth in the UK and Europe."

Related news

Related products

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Follow us

Products

View more

Webinars